Tag - TNXP

Markets

Tonix to develop vaccine in Kenya against monkeypox, smallpox

Tonix Pharmaceuticals (NASDAQ:TNXP) is collaborating with the Kenya Medical Research Institute to plan, seek regulatory approval for and conduct a Phase 1 clinical study in Kenya to develop Tonix’s TNX-801 as a vaccine...

July 28, 2022

Feature

Tonix has multiple shots on goal in CNS, immunology and infectious diseases

Tonix Pharmaceuticals (NASDAQ:TNXP) is engaged in a number of ongoing and planned clinical trials with a rich pipeline of products, including a Phase 3 clinical trial to treat fibromyalgia, along with a Phase 2 clinical...

July 19, 2022

Developments

Tonix Pharma TNX-1500 data presented at American Transplant Congress

Faculty at the Center for Transplantation Sciences, Massachusetts General Hospital, presented data at the 2022 American Transplant Congress about Tonix Pharmaceuticals’ (NASDAQ:TNXP) TNX-1500 product candidate in...

June 9, 2022

Developments

Tonix Pharmaceuticals meets target enrollment in Phase 3 fibromyalgia study

Tonix Pharmaceuticals (NASDAQ:TNXP) met its target enrollment of 470 patients in its Phase 3 study of TNX-102 SL for the management of fibromyalgia. TNX-102 SL is a non-opioid analgesic, administered daily at bedtime...

July 10, 2020

Developments

Tonix Pharmaceuticals enrolls first patient in Phase 3 fibromyalgia study

Tonix Pharmaceuticals (NASDAQ:TNXP) enrolled the first patient in its Phase 3 study of TNX-102 SL for the management of fibromyalgia. TNX-102 SL is a non-opioid analgesic, administered daily at bedtime. The trial will...

December 10, 2019

Tag - TNXP

Tonix to develop vaccine in Kenya against monkeypox, smallpox

Tonix has multiple shots on goal in CNS, immunology and infectious diseases

Tonix Pharma TNX-1500 data presented at American Transplant Congress

Tonix Pharmaceuticals meets target enrollment in Phase 3 fibromyalgia study

Tonix Pharmaceuticals enrolls first patient in Phase 3 fibromyalgia study

General

More